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ABSTRACT                                                   
INTRODUCTION 
     Atrophic gastritis is a risk factor for non-cardia gastric cancer, and gastro-oesophageal reflux 
disease (GORD) for oesophageal adenocarcinoma.  The role of atrophic gastritis and GORD in the 
aetiology of adenocarcinoma of the cardia remains unclear.  We have investigated the association 
between adenocarcinoma of the different regions of the upper gastrointestinal tract and atrophic 
gastritis and GORD symptoms. 
 
METHODS 
    138 patients with upper GI adenocarcinoma and age and sex matched controls were studied. 
Serum pepsinogen I/II was used as a marker of atrophic gastritis and categorised to five quintiles. 
History of GORD symptoms, smoking and H.pylori infection was incorporated in logistic regression 
analysis. Lauren classification of gastric cancer was used to subtype gastric and oesophageal 
adenocarcinoma. 
 
RESULTS 
     Non-cardia cancer was associated with atrophic gastritis but not with GORD symptoms; 55% of 
these cancers were intestinal subtype. Oesophageal adenocarcinoma was associated with GORD 
symptoms, but not with atrophic gastritis; 84% were intestinal subtype.  Cardia cancer was positively 
associated with both severe gastric atrophy [OR, 95% CI: 3.92 (1.77 – 8.67)] and with frequent 
GORD symptoms [OR, 95% CI: 10.08 (2.29 – 44.36)] though the latter was only apparent in the non-
atrophic subgroup and in the intestinal subtype. The association of cardia cancer with atrophy was 
stronger for the diffuse versus intestinal subtype and this was the converse of the association 
observed with non-cardia cancer.  
 
CONCLUSION  
     These findings indicate two distinct aetiologies of cardia cancer, one arising from severe atrophic 
gastritis and being of intestinal or diffuse subtype similar to non-cardia cancer, and one related to 
GORD and intestinal in subtype, similar to oesophageal adenocarcinoma.  Gastric atrophy, GORD 
symptoms and histological subtype may distinguish between gastric versus oesophageal origin of 
cardia cancer. 
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INTRODUCTION 
     There has been substantial progress in our understanding of the aetiology of 
adenocarcinoma of the stomach and oesophagus over recent decades.  Most cancers of 
the mid and distal stomach are a long-term complication of H. pylori-induced superficial 
gastritis.  They arise in the subgroup of subjects in whom the superficial gastritis progresses 
to atrophic gastritis and intestinal metaplasia accompanied with loss of gastric acid 
secreting capacity.(1, 2)  H. pylori-induced atrophic gastritis and hypochlorhydria are strong 
risk factors for both the intestinal and diffuse histological subtype of gastric cancer. (2, 3-6) 
Another important independent risk factor for gastric cancer is smoking.(7-9)  The fall in 
incidence  of adenocarcinoma of the stomach in the Western world over recent decades 
may be attributable in part to a falling incidence of both H. pylori infection and smoking.(6, 10) 
 
      A major risk factor for adenocarcinoma of the oesophagus is gastro-oesophageal reflux 
disease.(11)  The risk of oesophageal adenocarcinoma increases with both the frequency 
and duration of reflux symptoms.(11-13)  Frequent reflux of gastric juice containing acid, pepsin 
and bile is thought to induce columnar and intestinal metaplasia of the squamous mucosa of 
the distal oesophagus.(14, 15)  This metaplastic or Barrett’s oesophagus has a markedly 
increased risk of progressing to adenocarcinoma of the intestinal histological subtype.(16)  In 
contrast to adenocarcinoma of the mid and distal stomach, that of the oesophagus is 
negatively associated with H.pylori infection.(17)  The mechanism of this negative association 
is unclear but might  be related to a healthy acid secreting stomach being required to 
provide a refluxate of sufficient acidity to induce oesophageal damage.(18)  
 
     The aetiology of adenocarcinoma of the cardia and gastro-oesophageal junction is 
unclear and controversial. Understanding its aetiology is important as most 
adenocarcinomas of the upper gastrointestinal tract in the western world and in Northwest 
Iran involve the cardia and GE junction.(19, 20) The association of cardia cancer with H. pylori 
infection is confusing with some studies showing a negative association, some a positive 
and some no association.(21-27)  Some studies indicate that reflux symptoms are a risk factor 
for cardia cancer but a weaker risk factor than for oesophageal adenocarcinoma.(28)  A 
number of studies demonstrate smoking to be a risk factor for cardia cancer.(9, 29)   
 
     We recently studied the association between cancer of the cardia and serological 
evidence of both H. pylori infection and atrophic gastritis.(30)  This was performed in a nested 
case control study.  We observed a negative association with H.pylori infection but a 
positive association between atrophic gastritis and cardia cancer in those with the infection. 
We interpreted this as indicating dual aetiology of cardia cancer with some cases being due 
to H. pylori-induced atrophic gastritis and aetiologically resembling adenocarcinoma of the 
mid and distal stomach and others being of a different aetiology and associated with a non-
atrophic stomach. This latter group might be aetiologically similar to oesophageal 
adenocarcinoma. 
 
     In the current study we extended our investigation of the aetiology of cardia cancer by 
examining the association of both serological evidence of gastric atrophy and reflux 
symptoms with adenocarcinoma of the oesophagus, cardia and non-cardia regions of the 
stomach. This has been performed for the different histological subtypes of the cancer. We 
have also included H.pylori status and smoking history which are other well established risk 
factors for upper GI cancer.  This has been undertaken in a population in Northwest Iran 
with a high incidence of upper gastrointestinal cancer.(20, 31)  Our studies examining the 
association with both atrophic gastritis and reflux symptoms provide substantial support for 
cardia cancer being of two distinct aetiological subtypes, one similar to non-cardia cancer 
and the other similar to oesophageal adenocarcinoma. 
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METHOD & MATERIALS 
     This was a case-control study, conducted in Aras Clinic in Ardabil province in Northwest 
Iran. The area is a well-known high risk region for gastric cancer in general and gastric 
cardia cancer in particular. Aras Clinic is a referral centre for delivery of investigational, 
therapeutic and preventative services to all patients with upper gastrointestinal tract disease 
throughout the Ardabil province. It is specifically equipped and staffed through government 
funding to conduct research into the aetiology of upper GI cancer.  According to the latest 
estimates from the Ardabil Cancer Registry (32), half of all incident upper gastrointestinal 
cancers diagnosed in Ardabil province are recorded and evaluated in this Centre. The 
present study has been conducted by collaboration between the University of Glasgow 
(UK), Digestive Disease Research Centre (DDRC) of University of Tehran and Ardabil 
University of Medical Science. 
  
     In total, 152 consecutive eligible patients with gastric or oesophageal adenocarcinoma 
were identified.  We excluded 14 (9%) eligible patients for the following reasons:  poor co-
operation of patient due to severity of the illness (n=4), patient refusal (n=3) and insufficient 
or inappropriate serum or histologic samples (n=7).  Finally, 138 patients with gastric and 
oesophageal adenocarcinoma were enrolled into the study including 66 non-cardia, 53 
cardia and 19 oesophageal adenocarcinoma.  Diagnosis of cancer was made by 
microscopic verification of multiple endoscopic biopsies and all histologic slides were 
studied by two certified pathologists (N.R and R.D) and reviewed by third pathologist (M.S) 
to ensure meeting the protocol requirements in accordance with ICD-O-2. (33) In 
controversial cases, diagnosis of cancer was made only after joint agreement of all three 
pathologists. Cardia cancer was defined as tumours whose main bulk was within 2 cm distal 
to the gastro-oesophageal junction. Tumours located completely above the gastro-
oesophageal junction were considered to be oesophageal in origin.  Tumours located 
anywhere in the stomach other than the cardia were called non-cardia gastric cancer.  The 
histological subtypes according to the Lauren classification were also recorded.(34)   
 
     Prior to endoscopy, each patient had a standardised interview and details recorded 
regarding symptoms of reflux and smoking.  The average frequency of heartburn and/or 
acid regurgitation over the five years prior to presentation excluding those of last one year 
before diagnosis of cancer was recorded.  History of smoking was recorded as number of 
cigarettes per day and duration of smoking in years.  Alcohol consumption is extremely rare 
in this region.  The questionnaire employed was validated in a pilot study.(35)  A fasting blood 
sample was collected from each patient before endoscopy and serum stored at –70C for 
later serologic assessment.  
 
     In format of frequency-matched case control design, one control for each case of non-
cardia and cardia cancer and two controls for oesophageal adenocarcinoma patients were 
selected randomly from dyspeptic patients. They were attending the same Centre and their 
endoscopy had shown no evidence of peptic ulcer or tumours.  The controls were sex and 
age matched within 4 years.  The controls had undergone a similar interview to the cases 
and had also had serum stored prior to their endoscopy.  
    
     Serum pepsinogen I (PG I) and pepsinogen II (PG II) were assayed with enzyme 
immuno-sorbant assay (ELISA) methods using monoclonal antibodies to pepsinogen I and 
II (BIOHIT diagnostics, Biohit LTD, UK). All procedures were done according to 
manufacture’s instructions and results of PG I and PG II reported in µg/L. PG I/II ratio was 
calculated and reported in fraction.  We used serum PG I/II less than 2.5 as a serologic 
marker of atrophy as previously reported.(30) 
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      H.pylori infection was assessed by a serologic test using anti H.pylori Ig G antibody, 
supplied by the same manufacturer. A response titer more than 30 enzyme immuno units 
(EIU) was considered as positive for H.pylori infection. 
 
 
Statistical Analysis 
     Serum PG I/II as serologic marker of atrophy were presented in quintiles. The PG I/II 
data of each control group were used to make quintiles. Using binary logistic regression, 
relationship of PG I/II quintiles with each cancer was estimated as odds ratio (OR) with their 
95% confidence interval and related p values. PG I/II quintiles were treated as a categorical 
variable and 5th quintile was used as referent. Smoking, GORD symptoms and H.pylori 
serology were used as possible risk factors of cancer in univariate logistic regression. 
These variables were also used in multivariate model along with PG I/II quintiles. Smoking 
was presented as a dichotomous variable (1= Smoker: ≥ 10 cigarettes per day for at least 
10 years and no more than 5 years passed since stopping smoking, and 0=non-smoker 
including never smokers and those who smoked less than limits stated above). GORD 
symptoms were categorised as 0= never or less than one time per week, 1= one to two 
times per week, and 2= more than two times per week. In order to evaluate association of 
gastric atrophy with risk of different histological subtypes of upper GI adenocarcinoma, we 
used the serum PG I/II less than 2.5 as a serologic marker of atrophy.  Two sided p values 
less than 0.05 were considered statistically significant. The SPSS statistical software 
version 14.0 was used for most analysis.(36) 
 
RESULTS 
     Gastric non-cardia cancer: A total of 66 patients (49 male and 17 female, mean age 
65.9 + 6.5) with non-cardia cancer and similar number of controls were studied (Table 1). A 
monotonous decreasing risk of cancer was observed from the lowest to the highest quintiles 
of PG I/II (Fig 1a). In univariate analysis, the risk was maximal in patients with PG I/II ≤ 2.01 
with OR=15.76 (3.92 – 63.43).  Smoking also increased the risk of non-cardia cancer with 
OR=2.22 (1.11 - 4.46) (table 2).  GORD symptoms in both frequency levels showed a 
negative relationship with non-cardia cancer, but the association was only statistically 
significant in patients with GORD symptoms occurring 1-2 times per week. H.pylori 
seropositivity was detected in 93.9% of cases and 74.2% of controls and increased the risk 
of non-cardia in univariate analysis with OR=2.22 (1.11 - 4.46). 
 
     In multivariate analysis including smoking, GORD symptoms and H.pylori sero-status, 
first and second lowest PG I/II quintiles increased the risk of cancer with ORs (95% CI): 
21.47 (2.90 – 158.76) and 9.08 (1.10 – 75.29), respectively.  Smoking showed a more 
potent relationship with risk of non-cardia cancer, with OR (95% CI): 5.83 (2.11 – 16.11), 
GORD symptoms 1-2 times per week continued to show an inverse relationship, with OR 
(95% CI): 0.31 (0.11 – 0.85), The positive relationship between H.pylori infection and non-
cardia cancer no longer reached statistical significance OR (95% CI): 1.53 (0.57 -4.14). 
 
     According to the Lauren histological sub-classification of the non-cardia cancers, 36 
(54.5%) were intestinal subtype, 25 (37.9%) diffuse, and 5 (7.6%) cases mixed or 
unclassifiable. The intestinal subtype adenocarcinoma showed strong positive association 
with gastric atrophy (defined as PGI/II < 2.5) with OR (95% CI): 13.02 (4.39 – 38.61) in 
multivariate analysis. The diffuse subtype cancer was also associated less strongly with 
gastric atrophy with OR (95% CI): 3.07 (1.23 – 7.67).   
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     Oesophageal adenocarcinoma: 19 cases of oesophageal adenocarcinoma (12 male 
and 7 female, mean age 63.9 + 4.7) were compared with double the number of controls 
(Table 1).  In univariate analysis, GORD symptoms, in category of >2 times per week 
increased the risk of cancer with OR (95% CI) of 28.05 (4.74 – 165.91). In multivariate 
analysis, involving PG I/II, smoking and H.pylori sero-status, this relationship showed a 
decrease as OR (95% CI): 12.46 (1.80 – 86.47), (Table 3). Smoking also showed a positive 
relationship with the cancer, with OR (95% CI): 4.56 (1.01 – 20.68) which was not affected 
by other risk factors.  There was no association between oesophageal adenocarcinoma and 
atrophy. Frequency of H.pylori infection in patients with oesophageal adenocarcinoma was 
lower than their matched controls (47.4% vs. 73.7%). While inverse relationship between 
H.pylori and oesophageal adenocarcinoma was evident by univariate analysis (OR; 95% CI: 
0.25; 0.08 – 0.75), this negative relationship lost its statistical significance in multivariate 
analysis (OR; 95% CI: 0.43; 0.10 – 1.91). By the Lauren histologic classification, 16 (84.2%) 
of the 19 oesophageal adenocarcinomas were intestinal subtype. 
 
     Gastric cardia cancer: We studied 53 cases of cardia cancer (37 male and 16 female, 
mean age 63.8 + 7.1) and the same number of controls (Table 1).   A relationship between 
lowest quintile of PG I/II (≤ 2.37) and cardia cancer was noted in multivariate analysis [OR 
(95% CI): 3.92 (1.77–8.67)], (Table 4). However, there was a heterogenic relationship 
between atrophy and risk of cardia cancer with a relatively quadratic trend of risk of cardia 
cancer against different quintiles of PG I/II (Fig. 1b).  This contrasted with the linear 
association of non-cardia cancer with atrophy (Fig 1a).  There was also a positive 
association between cardia cancer and GORD symptoms at the level of >2 times per week 
having an OR (95% CI): 10.08 (2.29 – 44.36).  No significant effect of smoking was 
detected in our patients [OR (95% CI):1.40 (0.56-3.51)]. While serologic H.pylori infection 
was more frequent in cases than controls (83.0% vs. 73.6%), there was no significant 
relationship between cardia cancer and H.pylori infection [(OR (95% CI): 2.42 (0.84–7.02)]. 
 
      We further investigated the nature of the dual association of cardia cancer with atrophy 
and GORD using the dichotomised values.  The association between risk of cardia cancer 
and atrophy based on dichotomised definition PG I/II < 2.5, showed a significant 
relationship with OR (95% CI): 3.05 (1.32–7.06).  GORD symptoms dichotomised into >2 
times/week versus 0-2 times /week also showed a positive relationship with risk of cardia 
cancer with OR (95% CI): 4.40 (1.34–14.43). In order to further evaluate the relationship 
between atrophy, GORD and risk of cardia cancer, we recalculated the association of 
GORD and cardia cancer risk separately in atrophic and non-atrophic subgroups. This 
showed that the risk of cardia cancer was increased by GORD symptoms in non-atrophic 
patients, OR (95% CI):8.02 (2.25–28.58)], but not in atrophic patients (Fisher exact test p 
value= 1.00).  (Table 5, Fig 2). 
 
      In the cardia, 34 (64.2%) of tumours were classified histologically as intestinal subtype, 
16 (30.2%) were diffuse subtype and only 3 cases were mixed subtype or unclassifiable. 
Both the intestinal subtype and diffuse subtype were associated with gastric atrophy, OR 
(95% CI):3.64 (1.33–9.97), and OR (95% CI):17.71 (3.66–85.76) respectively. 
 
     The association of cardia cancer with GORD symptoms was also related to the 
histological subtype.  The intestinal subtype cardia cancer showed significant relationship 
with presence of GORD symptoms >2 times per week with OR (95% CI): 5.86 (1.68–20.39).  
In contrast, the association between GORD symptoms and diffuse subtype statistically was 
not significant [OR (95% CI): 2.83 (0.56–14.24)].  
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DISCUSSION 
     In our subjects with non-cardia gastric cancer, we found a strong association between 
serological evidence of gastric atrophy and risk of cancer and this is consistent with many 
previous studies.(37, 38)  Atrophic gastritis was associated with increased risk of both the 
intestinal and diffuse histological subtypes of non-cardia cancer but the association was 
stronger for the former as previously reported.(37, 39, 40)  Whereas, the intestinal subtype is 
nearly always a consequence of atrophic gastritis and intestinal metaplasia, the diffuse 
histological subtype sometimes develops in a non-atrophic stomach with a strong genetic 
predisposition being an important factor in some of these cases.(41, 42)   
 
     An association between H. pylori infection and non-cardia cancer was present in the 
univariate analysis consistent with previous reports (2).  However, this association was lost in 
multivariate analysis when atrophy and lifestyle factors were included.  This is consistent 
with H. pylori-induced atrophic gastritis being the pre-cancerous lesion rather than H. pylori 
infection itself. High prevalence of H.pylori infection in the background population shown in 
the current and previous studies can explain its weak relationship with gastric cancer risk.(43) 
   
   
     There was no significant association between frequent GORD symptoms (>2 
times/week) and non-cardia cancer in our study. However, the negative association 
between lees frequent GORD and non-cardia cancer can be explained by the atrophic 
gastritis protects against GORD symptoms, but it difficult to understand why this would not 
also protect against more frequent GORD. 
 
     We found that smoking was also a risk factor for non-cardia cancer as previously 
reported.  The extent of the association in univariate analysis [OR (95% CI): 2.22 (1.11-
4.46)] is consistent with most previous reports, suggesting smoking as a mild to moderate 
risk factor of non-cardia gastric cancer (8, 44, 45). Incorporating atrophy, H. pylori status and 
GORD symptoms into multivariate analysis enhanced the effect of smoking [OR (95%): 5.83 
(2.11–16.11)]. This indicates that the effect of smoking is not mediated through induction of 
atrophy but acts independent of the atrophic process. 
   
     In contrast to non-cardia cancer, oesophageal adenocarcinoma was positively 
associated with reflux symptoms.  This is consistent with previous reports and the currently 
accepted hypothesis that gastro-oesophageal reflux causes columnar and intestinal 
metaplasia which then progresses to intestinal subtype adenocarcinoma. (11, 46)  Consistent 
with this, the great majority of oesophageal adenocarcinomas in our study were of the 
intestinal histological subtype.  There was also a positive association with smoking as 
previously reported. (44, 47)   There was no association with gastric atrophy.  
 
     The main purpose of our study was to investigate the aetiology of cardia cancer and its 
relation to that of non-cardia and oesophageal adenocarcinoma.  Cardia cancer showed a 
complex relationship with gastric atrophy.  Severe gastric atrophy indicated by the lowest 
pepsinogen I/II quintile of <2.37 was associated with an increased risk of cardia cancer.  
However, unlike non-cardia cancer, there was no evidence of a progressive rise in cancer 
incidence with falling pepsinogen I/II ratio.  Rather, the relationship between pepsinogen I/II 
ratio and cancer risk showed a quadratic pattern with the risk of cardia cancer being highest 
for the lowest and highest pepsinogen I/II ratios and lowest for the intermediate ratios.  A 
plausible explanation for this complex association between cardia cancer and atrophic 
gastritis is that there are two distinct aetiologies of cardia cancer, one subgroup being 
associated with severe atrophic gastritis and resembling non-cardia cancer and the other 
subgroup unassociated or negatively associated with atrophic gastritis and aetiologically 
resembling oesophageal adenocarcinoma.   
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      Reflux symptoms were also found to be a risk factor for cardia cancer with GORD 
symptoms of >2 time per week increasing the risk of cardia cancer with OR (95% CI):10.08 
(2.29–44.36). Reflux symptoms have been reported previously to be a risk factor for cardia 
cancer but not as strong a risk factor as for oesophageal adenocarcinoma.(28)  In our study, 
we were able to investigate the interaction of reflux symptoms and atrophy in the aetiology 
of cardia cancer. This showed that reflux symptoms were associated with cardia cancer 
only in non-atrophic subjects, with a powerful OR (95% CI): 8.02 (2.25–28.58).  This is 
again consistent with two distinct aetiologies of cardia cancer, one being associated with 
atrophic gastritis and resembling non-cardia cancer and one associated with reflux and 
resembling oesophageal adenocarcinoma.  
  
     Further evidence of two distinct aetiologies of cardia cancer was apparent on examining 
the atrophy-cancer and GORD-cancer associations separately in the two histological 
subtypes. The association between atrophy and intestinal subtype adenocarcinoma was 
weaker in the cardia than in the non-cardia region of the stomach. This is consistent with 
the intestinal subtype cardia cancer being a mixture of tumours positively associated with 
atrophy (similar to non-cardia intestinal subtype adenocarcinomas) and tumours 
unassociated or negatively associated with atrophy (similar to oesophageal intestinal 
subtype adenocarcinoma). 
 
     The association of atrophy with diffuse cancer was stronger in the cardia than in the non-
cardia region of the stomach. This difference may be related to the different topographic 
distribution and extent of atrophy required to produce cancer at those two sites and the 
ability of PGI/II to detect the atrophy associated with cancer at these two sites.  Atrophy 
tends to start in the distal stomach at the junction between the antrum and body mucosa 
and progress proximally.(48, 49)  Cancers tend to develop within atrophic mucosa and thus 
cancers of the distal stomach may develop in subjects with less extensive atrophy than 
would be required to produce cancer up at the cardia region.  Furthermore, PGI/II is a 
reliable marker for detecting extensive atrophy involving the body mucosa but a poor 
marker for detecting early atrophy or that confined to the antral mucosa.(50, 51) 
 
     The association between GORD symptoms and cardia adenocarcinoma was also related 
to the histological subtype. GORD symptoms were strongly associated with the intestinal 
subtype cancers at the cardia and this relationship was similar to that for oesophageal 
adenocarcinoma.    This association with GORD symptoms and intestinal subtype 
adenocarcinoma at the cardia is consistent with some of these cancers occurring by the 
same mechanism as oesophageal adenocarcinoma which is also of the intestinal subtype; 
the reflux of gastric juice leading to columnar intestinal metaplasia, dysplasia and 
adenocarcinoma. In contrast, there was no relationship between GORD symptoms and 
diffuse subtype adenocarcinomas at the cardia. 
 
     Our findings thus support two distinct aetiologies of cardia cancer.  One subtype is 
associated with atrophic gastritis and may be of the intestinal, diffuse or mixed histological 
subtype.  It resembles non-cardia cancer and is likely to have arisen by the same process  
i.e. H. pylori-induced atrophic gastritis.  The other subtype is associated with GORD and is 
of the intestinal histological subtype.  It is likely to have a similar aetiology to oesophageal 
adenocarcinoma and to have arisen from acid reflux induced columnar intestinal metaplasia 
of original oesophageal squamous epithelium.  
  
     The above observations imply that there are not only two distinct aetiologies of cardia 
cancers but that the structural and functional state of the stomach associated with them is 
profoundly different.   One type is associated with a non-atrophic healthy gastric mucosa 
producing sufficient acid and pepsin to damage the mucosa of the gastro-oesophageal 
junction and lead to columnar intestinal metaplasia and intestinal subtype cancer.  The 
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other is associated with atrophic gastritis of sufficient severity and extent to involve the 
proximal stomach leading to the development of intestinal or diffuse subtype cancer from 
the atrophic gastric mucosa.  
 
     It is very difficult pre-operatively, during surgery or even at post-mortem examination to 
determine whether cancer of the cardia has arisen from original gastric or oesophageal 
mucosa.  Our study points to three factors likely to be useful in determining the origin of the 
cancer: (i) the histological subtype of the tumours, (ii) the state of the gastric mucosa distant 
from the tumour and (iii) the frequency of GORD symptoms (Fig. 2).  Diffuse histological 
tumour subtype strongly indicates gastric origin.  Intestinal subtype tumours with non-
atrophic gastric mucosa and frequent GORD symptoms are highly likely to be of 
oesophageal origin.  Intestinal subtype tumours with atrophic gastric mucosa and less 
frequent GORD symptoms are likely to be gastric in origin.  It is difficult to classify a 
proportion of the intestinal type cardia cancer.  This might be improved by more precise 
means of assessment of GORD and more accurate determination of the presence/absence 
of gastric atrophy, i.e. by histology of gastric mucosal biopsies.   
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Table 1: Frequency of risk factors of adenocarcinomas of non-cardia, oesophageal and cardia sub-sites, with matched controls 
 
 
Non-Cardia Oesophageal Cardia 
 Case (66) Control (66) Case (19) Control (38) Case (53) Control (53) 
PG I/II [mean (SD)] 2.01 (1.01) 3.46 (1.73) 4.76 (2.00) 3.43 (1.92) 3.39 (2.23) 4.19 (2.46) 
Smoking 
      
     Ever smoker 28 (42.4 %) 15 (22.7 %) 10 (52.6%) 9 (23.7 %) 19 (35.8 %) 12 (22.6 %) 
     Non smoker 38 (57.6 %) 51 (77.3 %) 9 (47.4%) 29 (76.3 %) 34 (64.2 %) 41 (77.4 %) 
GORD symptoms 
      
    <1 time per week 50 (75.8 %) 33 (50.0 %) 2 (10.5 %) 19 (50.0 %) 25 (47.2 %) 32 (60.4 %) 
    1 – 2 times per week 13 (19.7 %) 23 (34.8 %) 6 (31.6 %) 15 (39.5%) 14 (26.4 %) 17 (32.1 %) 
   >2 times per week 3 (4.5 %) 10 (15.2 %) 11 (57.9 %) 4 (10.5 %) 14 (26.4 %) 4 (7.5 %) 
H.pylori Sero-status 
      
     Positive 62 (93.9 %) 49 (74.2 %) 9 (47.4 %) 28 (73.7%) 44 (83.0 %) 39 (73.6 %) 
     Negative 4 (6.1 %) 17 (25.8 %) 10 (52.6 %) 10 (26.3%) 9 (17.0 %) 14 (26.4 %) 
Histological Subtype       
     Intestinal 36 (54.5 %) n/a 16 (84.2 %) n/a 34 (64.2 %) n/a 
     Diffuse 25 (37.9 %) n/a 1 (5.3 %) n/a 16 (30.2 %) n/a 
     Mixed / Unclassifiable 5 (7.6 %) n/a 2 (10.5 %) n/a 3 (5.7 %) n/a 
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Table 2: Relationship between risk of non-cardia gastric cancer and pepsinogen I /II, smoking, GORD symptoms and H.pylori sero-status 
 
 Univariate  Multivariate 
 Odds Ratio (95% CI) P Value  Odds Ratio (95% CI) P Value 
      PG Ratio quintiles  
5th: 5.125 – 7.445  1.00  1.00 
4th: 3.607 – 4.793  3.11 (0.62 - 15.58) 0.168  3.50 (0.45 – 27.37) 0.233 
3rd: 2.707 – 3.560  4.77 (1.07 - 21.21) 0.040  6.48 (0.78 – 54.01) 0.084 
2nd: 2.092 – 2.701 7.75 (1.81 - 33.16) 0.006  9.08 (1.10 – 75.29) 0.041 
1st: 0.189 – 2.011  15.76 (3.92 - 63.43) 0.000  21.47 (2.90 – 158.76) 0.003 
      Smoking  
Non smoker 1.00  1.00 
Ever smoker 2.22 (1.11 - 4.46) 0.025  5.83 (2.11 – 16.11) 0.001 
      GORD symptoms 
 
<1 time per week 1.00  1.00 
1 – 2 times per week 0.44 (0.20 - 0.96) 0.039  0.31 (0.11 - 0.85) 0.023 
>2 times per week 0.44 (0.17 - 1.10) 0.079  0.91 (0.18 – 4.64) 0.913 
      H.pylori Sero-status 
     
Negative 1.00   1.00  
Positive 2.22 (1.11 – 4.46) 0.025  1.53 (0.57 – 4.14) 0.401 
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Table 3: Relationship between risk of oesophageal adenocarcinoma and pepsinogen I /II, smoking, GORD symptoms and H.pylori sero-status 
 
 
Univariate  Multivariate 
 
Odds Ratio (95% CI) P Value  Odds Ratio (95% CI) P Value 
      PG Ratio quintiles 
 
5th: 4.482 – 9.409  1.00  1.00 
4th: 3.395 – 4.266  0.35 (0.07 – 1.72) 0.197  0.40 (0.05 – 3.29) 0.397 
3rd: 2.611 – 3.271 0.35 (0.07 – 1.72) 0.197  0.26 (0.03 – 2.22) 0.217 
2nd: 1.978 – 2.483 0.29 (0.06 – 1.46) 0.132  0.57 (0.08 – 4.11) 0.573 
1st: 1.155 – 1.959  0.26 (0.05 – 1.49) 0.131  0.41 (0.05 – 3.69) 0.427 
      Smoking 
 
Non smoker 1.00  1.00 
Ever smoker 4.70 (1.54 – 14.34) 0.007  4.56 (1.01 – 20.68) 0.049 
      GORD symptoms 
     
<1 time per week 1.00   1.00  
1 – 2 times per week 2.60 (0.65 – 10.36) 0.175  1.73 (0.33 – 9.11) 0.520 
>2 more times per week 28.05 (4.74 – 165.91) 0.001  12.46 (1.80 – 86.47) 0.011 
      H.pylori Sero-status 
Negative 1.00   1.00  
Positive 0.25 (0.08 – 0.75) 0.014  0.43 (0.10 – 1.91) 0.268 
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Table 4: Relationship between risk of gastric cardia cancer and pepsinogen I /II, smoking, GORD symptoms and H.pylori sero-status  
  
 
Univariate  Multivariate 
 
Odds Ratio (95% CI) P Value  Odds Ratio (95% CI) P Value 
      PG Ratio quintiles 
 
5th: 6.008 – 11.586 1.00  1.00 
4th: 3.848 – 6.004  1.10 (0.50 – 2.40) 0.817  0.92 (0.37 - 2.26) 0.852 
3rd: 3.062 – 3.734  0.50 (0.20 – 1.25) 0.138  0.62 (0.23- 1.71) 0.355 
2nd: 2.378 – 3.017  0.50 (0.20 – 1.25) 0.138  0.49 (0.18 - 1.38) 0.177 
1st: 0.479 – 2.370  2.77 (1.36 – 5.63) 0.005  3.92 (1.77 – 8.67) 0.001 
      Smoking 
 
Non smoker 1.00  1.00 
Ever smoker 1.70 (0.79 – 3.67) 0.175  1.40 (0.56 – 3.51) 0.476 
      GORD symptoms 
 
<1 time per week 1.00  1.00 
1 – 2 times per week 0.95 (0.40 – 2.29) 0.915  1.47 (0.54 – 4.00) 0.451 
>2 more times per week 3.15 (1.17 – 8.49) 0.024  10.08 (2.29 – 44.36) 0.002 
      H.pylori Sero-status 
Negative 1.00  1.00 
Positive 1.46 (0.68 – 3.14) 0.332  2.42 (0.84 – 7.02) 0.103 
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Table 5: Relationship between GORD symptoms and risk of gastric cardia cancer in atrophic versus non-atrophic subjects 
 
PG I/II GORD 
symptoms 
Cardia cancer Fisher’s Exact test OR 
  Case Control P value (two-sided) (95% CI) 
> 2 / week 1 0 
0-2 / week 24 12 Atrophic 
Total 25 12 
1.000 NA 
> 2 / week 13 4 
0-2 / week 15 37 Non-atrophic 
Total 28 41 
0.001 8.02 (2.25 – 28.58) 
 
 
 
 
 
 
 
 
 
 
 o
n
 26 Novem
ber 2007 
gut.bmj.com
D
ow
nloaded from
 
 19
 
 
 
 
 
 
Figure legends: 
 
 
Fig 1: Relationship between severity of atrophic gastritis, expressed by serum PG I/II and risk of gastric cancer at non-cardia (A) and cardia 
subsites (B). The first quintile of PG I/II indicates greatest degree of atrophy and 5th quintile least atrophy. 
 
Fig 2: This presents the PG I/II values in the individual patients with oesophageal, cardia and non-cardia cancers.  The cardia cancers are 
grouped according to histological subtype and frequency of GORD symptoms.  Atrophy is indicated by PG I/II values of <2.5 (broken 
line).  
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